WO2014207181A1 - Utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci, pour prévenir et/ou traiter les odeurs corporelles et pour diagnostiquer une transpiration malodorante - Google Patents

Utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci, pour prévenir et/ou traiter les odeurs corporelles et pour diagnostiquer une transpiration malodorante Download PDF

Info

Publication number
WO2014207181A1
WO2014207181A1 PCT/EP2014/063655 EP2014063655W WO2014207181A1 WO 2014207181 A1 WO2014207181 A1 WO 2014207181A1 EP 2014063655 W EP2014063655 W EP 2014063655W WO 2014207181 A1 WO2014207181 A1 WO 2014207181A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid sequence
seq
amino acid
odorous
skin
Prior art date
Application number
PCT/EP2014/063655
Other languages
English (en)
Inventor
Claire Marie BENOIT-JAY
Dominique Bernard
Mark Donovan
Stephanie Nouveau
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2014207181A1 publication Critical patent/WO2014207181A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • the present invention relates to the cosmetic use of dermcidin, or analogues or fragments thereof or of a composition containing the same, for preventing and/or treating body odour, particularly from the armpits and the feet, and also for diagnosing odorous sweat.
  • the invention also relates to a process for applying the abovementioned cosmetic composition for preventing and/or treating body odour.
  • the present invention also relates to the use of a biomarker for diagnosing odorous sweat.
  • the invention also relates to a process for screening active agents that are capable of preventing or treating body odour.
  • the term "skin" means the entire epidermis of the human body. More particularly, the skin under consideration in the present invention is preferably the skin of the armpits, the scalp and the feet, and preferably the skin of the armpits.
  • body odour is given in the publication Cosmetic Science and Technology Series - 1988/Volume 7 chap. 10 - IIIc.
  • body odour is caused by odorous sweat.
  • the anatomy and physiology of the skin vary from one part of the body to another.
  • the skin contains sebaceous and sweat glands whose excretions consist, inter alia, of water, amino acids, urea, electrolytes and/or specific fatty acids.
  • excretions constitute an excellent nutritive medium for all of the flora, mainly the bacterial flora, which colonizes the skin, the components thereof, once in contact with the air, undergo chemical reactions, for instance oxidation, which degrade them and give rise to products responsible for body odour that may occasionally prove to be disagreeable.
  • cutaneous excretions are not the only factors responsible for body odour caused by odorous sweat.
  • the cutaneous flora itself is partly responsible therefor.
  • the underarm microflora is mainly composed of gram-positive bacteria, such as staphylococci (e.g. S. epidermidis, S. hominis, etc.), coryneforms (more particularly C. xerosis), micrococci (e.g. M. luteus), Brevibacteria and Propionibacteria.
  • staphylococci e.g. S. epidermidis, S. hominis, etc.
  • coryneforms more particularly C. xerosis
  • micrococci e.g. M. luteus
  • Brevibacteria e.g. M. luteus
  • a cosmetic or dermatological composition in particular as an anti-odour active agent.
  • One subject of the invention is thus the use of a cosmetic composition containing at least one amino acid sequence of dermcidin, and more particularly of the iso forms 1 and 2 thereof (DCD-1 and DCD-2), or of a peptide derived from this protein, an analogue or fragment thereof or a nucleic acid sequence coding for a peptide in accordance with the invention, for preventing and/or treating body odour, particularly from the armpits, the scalp and the feet, and also for diagnosing odorous skin.
  • the invention also relates to a cosmetic treatment process in which a cosmetic composition comprising an amino acid sequence of dermcidin, and more particularly of the isoform 1 or 2 thereof, an analogue or fragment thereof and/or preferably at least one peptide in accordance with the invention, at least one nucleic acid sequence coding for a peptide in accordance with the invention, or at least one modulator of the expression or activity, especially biological, of said peptide, is applied to the skin.
  • Another aspect of the invention is the use of dermcidin, and more particularly of the isoform 1 or 2 thereof, an analogue or a fragment thereof and/or preferably at least one peptide in accordance with the invention, at least one nucleic acid sequence coding for a peptide in accordance with the invention, especially as a biomarker for diagnosing odorous skin and/or odorous sweat.
  • the invention relates to the use of dermcidin, and more particularly of the isoform 1 or 2 thereof, an analogue or a fragment thereof and/or preferably at least one peptide in accordance with the invention, at least one nucleic acid sequence coding for a peptide in accordance with the invention, as a biomarker for evaluating the level of odour of the skin and/or of sweat.
  • the invention also relates to a process for screening active agents that are capable of modulating the expression or activity, especially biological, of said peptide.
  • DCD/PIF Dermcidin/Protease Inducing Factor
  • the protein precursor After proteolytic post-translational processing (essentially by cathepsin D) which takes place in sweat (Baechle, Flad et al, 2006), the protein precursor gives rise to numerous peptides whose length ranges from 25 to 48 aa (Flad, Bogumil et al, 2002). Some of these peptides show antimicrobial activity against microorganisms such as S. aureus, E. coli, Enterococcus faecalis, Candida albicans, etc. The antimicrobial peptides are derived from the C-terminal part of the protein.
  • the activity of these peptides is independent of their charge (Steffen, Rieg et al., 2006) and is thought to proceed via a step of interaction with bacterial phospholipids (Li, Rigby et al., 2009).
  • the N-terminal part of the protein consists of a biologically active factor that promotes cell survival (Cunningham, Hodge et al., 1998).
  • the decrease in DCD observed in the sweat of atopic skin types may partly explain the microbial susceptibilities of this skin type (Rieg, Steffen et al., 2005).
  • Some of its antimicrobial fragments and also of its N-terminal part are capable of stimulating the production of cytokines/chemokines via keratinocytes or other cell types involving it even more in the regulation of cutaneous immunity (Watchorn, Dowidar et al., 2005; Niyonsaba, Suzuki et al., 2009).
  • DCD as a particularly sensitive specific marker of the presence of traces of sweat by RT-PCR or by ELISA that can be used in the medico-legal field (Sakurada, Akutsu et al., 2009).
  • Amino acid and nucleic acid sequences dermcidin or preproteolysin is a 110-amino acid protein (SEQ ID NO: 1) comprising a 19-amino acid signal peptide (SEQ ID NO: 3) whose gene is located on chromosome 12, locus 12ql3.1.
  • SEQ ID NO: 1 the shorter one
  • isoform 1 SEQ ID NO: 4
  • isoform 2 SEQ ID NO: 5
  • dermcidin is a 90-amino acid protein having the sequence SEQ ID NO: 2.
  • peptides derived from dermcidin maturation show antimicrobial activity against various microorganisms, such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis or Candida albicans.
  • the antimicrobial peptides are derived from the C-terminal part of the protein and do not correspond to all of the identified peptides represented by SEQ ID NO 6 to SEQ ID NO 26.
  • analogue of an amino acid sequence is intended to denote any amino acid sequence having at least 85%, preferably at least 90%, more preferentially at least 95% and even more preferably at least 99% sequence identity with said sequence, and biological activity of the same nature.
  • biological activity of the same nature with regard to an amino acid sequence according to the invention means the antimicrobial properties or the properties of stimulation of cell survival and/or proliferation usually attributed to dermcidin.
  • sequence identity may be determined by visual comparison or by means of any information technology tool generally used in the field, such as the Blast programs available on www.ncbi.nlm.nih.gov and used with the default parameters.
  • An analogue in accordance with the invention may be a peptidomimetic agent.
  • An analogue of an amino acid sequence of the invention may result from modifications derived from mutation or variation in the peptide sequences according to the invention originating either from the deletion or insertion of one or more amino acids, or from the substitution of one or more amino acids, or alternatively from alternative splicing. Several of these modifications may be combined.
  • an analogue of an amino acid sequence of the invention may comprise conservative substitutions relative to this amino acid sequence.
  • hydropathic index is an index assigned to amino acids according to their hydrophobicity and their charge (Kyte et al. (1982), J. Mol. Biol, 157: 105).
  • An amino acid sequence or an analogue thereof targeted by the present invention may be an amino acid sequence that has undergone one or more post- translational maturations.
  • post-translational maturation(s) is intended to encompass all the modifications that an amino acid sequence is liable to undergo after its synthesis in a cell, for instance one or more phosphorylations, deamidation, one or more thiolations, one or more acetylations, one or more glycosylations, one or more lipidations, such as a farnesylation or a palmitoylation, a structural rearrangement such as disulfide bridge formation and/or cleavage within the peptide sequence.
  • An analogue of an amino acid sequence moreover has substantially the same biological activity as this amino acid sequence.
  • a primary amino acid sequence may comprise sites specifically recognized by enzymes of protease type, such as trypsin, which, once the recognition of these sites is effective, will induce cleavage of the sequence by proteolysis.
  • protease type such as trypsin
  • This proteolysis results in the generation of various peptides, or fragments of amino acid sequences of the invention. Consequently, the invention also covers fragments of dermcidin or of the iso forms 1 and 2 thereof or peptides thereof, derived, where appropriate, from its proteolysis.
  • fragment of an amino acid sequence means any portion of the amino acid sequence in accordance with the invention comprising from 3 to 48 consecutive amino acids of said sequence.
  • an amino acid sequence that is suitable for use in the invention may be an amino acid sequence represented by a sequence chosen from SEQ ID NO: 4 to 26, especially from SEQ ID NO: 6 to SEQ ID NO: 26, or an analogue or fragment thereof.
  • a peptide that is suitable for use in the invention may also be a natural or synthetic amino acid sequence, which may be obtained, where appropriate, after enzymatic or chemical hydrolysis of dermcidin or by chemical or biological synthesis, or alternatively any natural or synthetic amino acid sequence whose sequence totally or partially comprises an abovementioned amino acid sequence.
  • the present invention relates, per se, to an isolated peptide represented by an amino acid sequence chosen from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 and/or SEQ ID NO: 26, or an analogue or fragment thereof.
  • the present invention also relates to cosmetic compositions comprising in a cosmetically acceptable medium an effective amount of at least one amino acid sequence of the invention.
  • the invention relates to a cosmetic composition
  • a cosmetic composition comprising a peptide represented by an amino acid sequence chosen from SEQ ID NO: 6 to SEQ ID NO: 26, or an analogue or fragment thereof.
  • compositions according to the invention are those conventionally used in the fields under consideration.
  • the amount of amino acid sequence, or of nucleic acid sequence of the invention, or of active agent in accordance with the invention contained in a composition of the invention also known as the "effective amount" depends, of course, on the nature of the active agent and of the desired effect and may thus vary within a wide range.
  • a composition may contain an amino acid sequence, or an active agent in accordance with the invention, in an amount representing from 0.00001% to 5% of the total weight of the composition, in particular in an amount representing from 0.001% to 2% of the total weight of the composition and more particularly in an amount representing from 0.1% to 1% of the total weight of the composition.
  • the term "effective amount" of a compound of the invention means an amount of this compound that is sufficient and necessary to obtain a desired effect, and more particularly to prevent and/or treat body odour.
  • prevent means reducing the risk of manifestation of a given phenomenon, i.e. in the present invention, body odour.
  • the cosmetic composition according to the invention may comprise, besides SEQ ID NO 4 or SEQ ID NO 5 or a peptide derived from these proteins, an analogue or a fragment thereof in accordance with the invention, deodorant or antiperspirant active agents conventionally used in deodorant or antiperspirant compositions.
  • deodorant active agents examples include water- soluble zinc salts, such as zinc pyrrolidonecarboxylate (more commonly known as zinc pidolate), zinc sulfate, zinc chloride, zinc lactate, zinc gluconate and zinc phenolsulfonate, and bactericides such as 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Triclosan) or 3,7,11- trimethy ldodeca-2 ,5,10-trieno 1 (Farneso 1) .
  • zinc pyrrolidonecarboxylate more commonly known as zinc pidolate
  • zinc sulfate zinc chloride
  • zinc lactate zinc lactate
  • zinc gluconate zinc gluconate
  • zinc phenolsulfonate examples include water- soluble zinc salts, such as 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Triclosan) or 3,7,11- trimethy ldodeca-2 ,
  • antiperspirant active agents examples include aluminium salts, such as aluminium chloride and aluminium hydroxyhalides, aluminium/zirconium hydroxyhalides, for instance hydroxyzirconyl salts, complexes of metals (such as aluminium or zirconium) with an amino acid (for instance glycine) and as described in patent US-3 792 068.
  • aluminium salts such as aluminium chloride and aluminium hydroxyhalides
  • aluminium/zirconium hydroxyhalides for instance hydroxyzirconyl salts
  • complexes of metals such as aluminium or zirconium
  • an amino acid for instance glycine
  • the cosmetic composition according to the invention is conventionally formulated according to the presentation form for which it is intended.
  • a cosmetically acceptable vehicle which may especially be essentially aqueous, or contain organic solvents and especially C1 -C4 monoalcohols, preferably ethanol, to accelerate the evaporation of the product, or propylene glycol, dipropylene glycol or ethers thereof.
  • the cosmetic composition according to the invention may also be formulated as a water- in-oil or oil-in-water emulsion or as a water-in-oil-in-water triple emulsion (such emulsions are known and described, for example, by C. Fox in "Cosmetics and Toiletries” - November 1986 - Vol. 101 - pages 101-112).
  • the cosmetic composition according to the invention may also comprise cosmetic adjuvants chosen from fatty substances, gelling agents, emollients, softeners, antioxidants, opacifiers, stabilizers, antifoams, moisturizers, vitamins, fragrances, preserving agents, surfactants, fillers, sequestrants, polymers, propellants, acidifying or basifying agents, dyes, pigments, thickeners, or any other ingredient usually used in cosmetics for this type of application. Needless to say, a person skilled in the art will take care to select this or these optional additional compounds such that the advantageous properties intrinsically associated with the cosmetic composition in accordance with the invention are not, or are not substantially, adversely affected by the envisaged addition(s).
  • cosmetic adjuvants chosen from fatty substances, gelling agents, emollients, softeners, antioxidants, opacifiers, stabilizers, antifoams, moisturizers, vitamins, fragrances, preserving agents, surfactants, fillers, sequestrants, polymers,
  • the surfactants are preferably chosen from anionic, amphoteric and nonionic surfactants.
  • the fatty substances may consist of an oil or a wax or a mixture thereof, petroleum jelly, paraffin, lanolin, hydrogenated lanolin or acetylated lanolin.
  • the cosmetic composition according to the invention may thus be in the form of a lotion, a cream or a fluid gel dispensed as an aerosol spray, in a pump-dispenser bottle or as a roll- on, in the form of a thick cream dispensed in a tube and in the form of a stick or a powder, and, in this regard, may contain ingredients and propellants generally used in products of this type that are well known to those skilled in the art.
  • the present invention relates to the cosmetic use of an effective amount of at least one amino acid sequence as an active agent for preventing and/or treating body odour.
  • the present invention relates to a cosmetic, or non-therapeutic, process for preventing and/or treating body odour in an individual in need thereof, the process comprising at least one step consisting in administering to said individual at least one composition comprising as an active agent at least one amino acid sequence of the invention, especially as defined above.
  • a process or a use of the invention make it possible to prevent and/or treat body odour.
  • a process of the invention may comprise the topical application to at least a part of the skin of an individual in need thereof, in particular to the skin of the armpits, the scalp and/or the feet, of at least one coat of a topical composition of the invention.
  • a cosmetic process according to the invention may be performed daily, for example at a rate of a single application per day or of an administration split into two or three times per day, for example once in the morning and once in the evening.
  • a cosmetic process according to the invention may be performed over a time period ranging from one week to several weeks, or even several months, this period moreover possibly being repeated after periods without treatment, for several months or even several years.
  • a cosmetic process according to the invention it is possible to envision application of a cosmetic composition of the invention, for example, at a rate of 1, 2 or 3 times per day, or more, and generally over an extended period of at least 4 weeks, or even 4 to 15 weeks, with, where appropriate, one or more periods of stoppage.
  • the inventors observed that the level of expression of peptides derived from SEQ ID NO 4 and SEQ ID NO 5 and identified by the sequences SEQ ID NO: 6 to SEQ ID NO: 26 were systematically reduced in the odorous sweat when compared with the non-odorous sweat.
  • this antimicrobial skin surface protein and more particularly the iso forms thereof characterized by the sequence SEQ ID NO 4 and SEQ ID NO 5 and even more particularly the peptides identified by SEQ ID NO 6 to SEQ ID NO 26 have never been classified as a variant of odorous sweat and even less so as one of the most pertinent biomarkers emerging from studies of this type.
  • the isoform 2 has itself never been described in sweat.
  • the present invention relates to the use of at least one amino acid sequence of the invention as a biomarker of the level of body odour of the skin.
  • a use in accordance with the invention makes it possible to characterize the level of body odour.
  • biomarker means a molecule or the activity of a molecule whose presence, content or degree of activity is characteristic of a biological, physiological or pathological process, or of the impact or effect induced by the administration of an active agent or of a physical treatment on such a process.
  • a decrease in the activity, expression or maturation of said biomarker may be indicative of odorous skin and/or of odorous sweat.
  • a decrease or an increase in the activity, expression or maturation of said biomarker may be determined by comparison with a reference measurement obtained according to any method known to those skilled in the art.
  • a “reference measurement” with regard to a given parameter is a qualitative or quantitative measurement of this parameter performed under “control” or “normal” conditions, for example determined in a reference sample, or determined in a sample in the absence of a treatment presumed to have an effect on the parameter.
  • a reference measurement for an amino acid sequence or a nucleic acid sequence in accordance with the invention may be a quantitative or qualitative value relative to the expression, maturation or activity of said sequences determined in a sample of non-odorous or odorous skin or sweat before a cosmetic treatment.
  • a reference measurement is a statistical measurement, i.e. a measurement that has been repeated on various samples so as to obtain an average.
  • the reference measurement may be taken in parallel with or sequentially to the test measurement.
  • a comparison of the test measurement with a reference measurement, and an observation of a deviation or an absence of deviation between the two measurements makes it possible to draw information regarding the measured parameter for example the decrease or increase in the expression, maturation or activity of an amino acid sequence in accordance with the invention.
  • Such information may be subsequently used to determine the odorous nature of a skin and/or sweat and to identify the specific disequilibria thereof.
  • the invention relates to a process, in particular an in vitro or ex vivo process, for characterizing the level of body odour of the skin and/or of sweat.
  • the qualitative or quantitative measurement of the expression, maturation or activity of an amino acid sequence of the invention may be performed using any method known to those skilled in the art.
  • immunoenzymatic assay methods using protein solutions which are more quantitative and sensitive, may in particular be used.
  • These ELISA-type methods combine pairings of target-antigen-specific capture antibody and detection antibody.
  • Commercial antibodies or specifically developed monoclonal, polyclonal or recombinant antibodies may be used.
  • High-capacity multiplex ELISA techniques may also be used. Mention may thus be made of the multiplex approach of the type such as antibodies on Luminex beads (for example Bioplex from Bio-Rad) or of the type such as antibodies on a flat surface (antibody arrays) (for example the approach proposed by the company MesoScale Discovery).
  • a novel technique based on "quench body" antibodies proposed by the Japanese company Ushio makes it possible to use only an antibody.
  • an antibody may be marked with a directly detectable substance (for example with a GFP tag) or a substance that is detectable by reaction with another reagent.
  • antibody is intended to denote, generally, monoclonal or polyclonal antibodies, and also immunoglobulin fragments capable of binding an antigen and which can be produced by any genetic engineering technique known to those skilled in the art or by enzymatic or chemical cleavage of an intact antibody.
  • An antibody that may be used as a tool for evaluating the condition of an epidermis may be obtained via any process known to those skilled in the art, as described in Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990).
  • an amino acid sequence of the invention may be advantageous to detect the expression of an amino acid sequence of the invention by means of an "iTRAQ" differential proteomic method.
  • the determination of a state of the skin and/or of sweat, or characterization of the efficacy of a cosmetic treatment of the skin and/or of sweat may be performed by measuring the variation in the expression of an amino acid sequence of the invention, and preferably represented by a sequence chosen from SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or an analogue or fragment thereof.
  • the processes of the invention are particularly advantageous since the implementation thereof does not require recourse to an invasive technique.
  • a sample of liquid sweat may thus be directly taken and analysed via a conventional analytical technique known to those skilled in the art.
  • one of the markers of the invention may be used for the purposes of more efficient and more rigorous preclinical selection, of individuals, with a view to evaluating the efficacy of a cosmetic treatment or of a cosmetic active agent for reducing body odour.
  • a biomarker of the invention may advantageously be used for evaluating the efficacy of an active agent, in vitro, ex vivo or in vivo.
  • a biomarker of the invention may be used for establishing personalized advice for a cosmetic treatment for an individual according to said individual's skin biomarker expression profile.
  • the present invention relates to the use (i) of at least one amino acid sequence of the invention, for screening active agents or physical treatments that are capable of modulating the activity, expression or maturation of said amino acid sequence.
  • the term "expression" with regard to an amino acid sequence means its content or the variation of its content relative to a reference.
  • the term “maturation” with regard to an amino acid sequence means the modifications that follow their synthesis in a cell environment.
  • the term “maturation” means the post-translational modifications, such as glycosylation or farnesylation of certain amino acids, or the proteolytic steps leading to the removal of "signal” or “secretory” sequences or to the release of sequences having particular biological properties.
  • the term "activity" means, with regard to an amino acid sequence, for example a protein or a peptide, the biological activity of the amino acid sequence, where appropriate after maturation, such as an enzymatic activity, an agonist or antagonist activity with respect to a receptor, an enzyme-activating or -inhibiting activity, a "structural” activity, or an antimicrobial activity.
  • the present invention relates to the use (i) of at least one amino acid sequence of the invention, for characterizing the level of body odour of the skin and/or of sweat.
  • the present invention makes it possible to propose novel active agents that are suitable for preventing and/or treating odorous skin and/or odorous sweat.
  • the aim of the present invention is to satisfy these needs.
  • the present invention relates to the use of an amino acid sequence, for the screening or in a process of screening, in particular in vitro or ex vivo, of active agents that are particularly suitable for preventing and/or treating odorous skin and/or odorous sweat.
  • the screening active agents may especially be suitable for preventing and/or treating odorous skin and/or odorous sweat.
  • a use or a process of the invention may comprise the comparison of a measurement of the activity, expression or maturation of an amino acid sequence or of a nucleic acid sequence in accordance with the invention, with a reference measurement.
  • a reference measurement may be as previously defined.
  • a reference measurement may be a quantitative or qualitative value relating to the expression, maturation or activity of said sequences, determined in a sample in the absence of active agent or of physical treatment tested.
  • a reference measurement may be obtained by repeating the steps of a process of the invention, and especially steps a), b) and c) of a process of the invention as defined previously, in the absence of biological or chemical compounds to be tested.
  • a comparison of the test measurement with a reference measurement, and an observation of a deviation or an absence of deviation between the two measurements makes it possible to draw information regarding the effect of the active agent tested.
  • the quantitative or qualitative determination of the expression, maturation or activity of an amino acid sequence of the invention may be performed via any method known to those skilled in the art, and especially as described previously.
  • the screening of an active agent that is capable of modulating the activity of an amino acid sequence of the invention may be performed by measuring the activity or the expression of a target molecule belonging to the signalling or metabolic pathways in which said amino acid sequence may be involved, for instance a reporter gene system.
  • a process of the invention may be performed in an acellular system, i.e. in a system which does not comprise cells but which reproduces cell functions, or in an isolated cell sample.
  • a process in accordance with the invention may be performed on an isolated cell sample, an acellular sample, on an isolated amino acid sequence or on an isolated nucleic acid sequence of the invention, especially from a sample of liquid sweat.
  • the screening of an active agent or of a physical treatment may be performed by measuring the variation of the expression, in the presence and in the absence of the screened active agent, of an amino acid sequence of the invention, and preferably represented by the sequence chosen from SEQ ID NO: 4 to SEQ ID NO: 26, or an analogue or fragment thereof.
  • an active agent of the invention may be an agent that stimulates the activity, expression or maturation of an amino acid sequence of the invention.
  • the term “one” should be understood, unless otherwise indicated, as meaning "at least one”.
  • EXAMPLE 1 iTRAQ proteomic study of the expression profile of dermcidin in odorous and non-odorous sweat 1- Materials and methods
  • each protein extract is digested with a proteolytic enzyme: trypsin.
  • each peptide mixture obtained is labelled with an isobaric tag having a total mass of 145, comprising a "reporter” group of mass 114, 115, 116 or 117, and a "balance" group of mass 31, 30, 29 or 28, linked together via an MS fragmentation site.
  • the labelling is obtained by reaction of the peptide-reactive group of each tag with the primary amines of the peptides (N-terminal end of the peptides or the side chain of lysines or tyrosines.
  • the samples are pooled and analysed by mass spectrometry.
  • a given peptide, present in several samples, will have an identical parent mass, but its MS/MS fragmentation spectrum will generate the mass of the reporter group that is characteristic for each of the iTRAQ reagents. Comparison of the intensity of each reporter ion (114, 115, 116 or 117) then allows quantification of the peptide.
  • the iTRAQ method is more precisely described by Zieske (J. Exp. Bot., 2006, 57: 1501) or Wiese et al. (Proteomics, 2007, 7: 340). b- Collection and treatment of the sweat samples
  • the liquid sweat was collected from healthy male individuals after 45 minutes in a sauna. 24 individuals were selected for this peptidomic analysis: 12 UAO- individuals (odour intensity between 1 and 3.5) and 12 UAO+ individuals (odour intensity between 6 and 9). The samples collected are stored at -20°C before the analysis.
  • pool 1 (UAO- pool 1): individuals 6, 15 and 30
  • pool 2 (UAO- pool 2): individuals 28, 36 and 40
  • pool 3 (UAO- pool 3): individuals 12, 17 and 26
  • pool 4 (UAO- pool 4): individuals 25, 27 and 34
  • pool 1 (UAO+ pool 1): individuals 13, 33 and 35
  • pool 2 (UAO+ pool 2): individuals 18, 23 and 41
  • pool 3 (UAO+ pool 3): individuals 31, 46 and 47
  • pool 4 (UAO+ pool 4): individuals 32, 44 and 45
  • EXAMPLE 2 ELISA study of the expression profile of dermcidin in odorous and non- odorous sweat (Figure 1). The samples of underarm sweat (odorous and non-odorous) were centrifuged for 8 minutes at 4°C in order to remove the corneocytes and the bacteria. The supernatants were stored at -20°C until the analysis. ELISA Assay
  • the amount of dermcidin was measured in 25 ⁇ of supernatants.
  • the capture antibody (AbDserotec) was fixed to the bottom of the wells at a concentration of 200 ⁇ g/ml on 96- well plates (MesoScale).
  • the calibration curve was established with concentrations of DCD-1 ranging from 0.4 to 25 ng/ml.
  • concentrations of DCD-1 ranging from 0.4 to 25 ng/ml.
  • the wells were saturated in buffer for one hour at room temperature.
  • the plates were washed five times with Tris washing buffer before adding to each well 150 ⁇ of IX READ buffer T.
  • the plates were read with a Sector Imager 6000 machine.
  • the amount of DCD-1 was measured from the calibration curve in ng/ml.
  • the inventors showed that the protein DCD-1 was significantly under-expressed in the samples of odorous sweat (Figure 1).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Cette invention concerne l'utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci ou d'une composition la contenant, pour prévenir et/ou traiter les odeurs corporelles, en particulier celles émanant des aisselles et des pieds, et pour diagnostiquer une transpiration malodorante. Cette invention concerne également un procédé d'application de la composition cosmétique précitée pour prévenir et/ou traiter les odeurs corporelles. L'utilisation d'un biomarqueur pour le diagnostic d'une transpiration malodorante est en outre décrite.
PCT/EP2014/063655 2013-06-27 2014-06-27 Utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci, pour prévenir et/ou traiter les odeurs corporelles et pour diagnostiquer une transpiration malodorante WO2014207181A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1356206 2013-06-27
FR1356206A FR3011739A1 (fr) 2013-06-27 2013-06-27 Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci pour prevenir et/ou traiter les odeurs corporelles ainsi que pour le diagnostique des sueurs odorantes

Publications (1)

Publication Number Publication Date
WO2014207181A1 true WO2014207181A1 (fr) 2014-12-31

Family

ID=49753267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/063655 WO2014207181A1 (fr) 2013-06-27 2014-06-27 Utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci, pour prévenir et/ou traiter les odeurs corporelles et pour diagnostiquer une transpiration malodorante

Country Status (2)

Country Link
FR (1) FR3011739A1 (fr)
WO (1) WO2014207181A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106906180A (zh) * 2016-12-28 2017-06-30 里程 一种具有生物活化作用的复合添加剂及其制备方法和用途
FR3060359A1 (fr) * 2016-12-19 2018-06-22 L'oreal Compositions cosmetiques ou dermatologiques comprenant au moins une sequence d’acide amine issue de la proteine xp32
EP3360891A1 (fr) 2017-02-14 2018-08-15 Karlsruher Institut für Technologie Peptides de pénétration cellulaire d'origine humaine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100895A2 (fr) * 2001-06-13 2002-12-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptide a action antimicrobienne
US20080050398A1 (en) * 2005-03-29 2008-02-28 Dirk Bockmuehl Composition Comprising Beta-Defensin 2
WO2011036174A1 (fr) * 2009-09-25 2011-03-31 B.R.A.I.N. Biotechnology Research And Information Network Ag Nouveau procédé de production d'un peptide antimicrobien
FR2954136A1 (fr) * 2009-12-17 2011-06-24 Oreal Composition deodorante a base de peptides antimicrobiens et procede de traitement des odeurs corporelles
WO2011132176A1 (fr) * 2010-04-23 2011-10-27 L'oreal Utilisation cosmétique d'un lysat d'espèces de bifidobacterium pour le traitement des odeurs corporelles
WO2012038929A1 (fr) * 2010-09-24 2012-03-29 L'oreal Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci
FR2980360A1 (fr) * 2011-09-27 2013-03-29 Oreal Utilisation cosmetique de l'hesperidine ou de l'un de ses derives dans la prevention et/ou le traitement des odeurs corporelles.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100895A2 (fr) * 2001-06-13 2002-12-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptide a action antimicrobienne
US20080050398A1 (en) * 2005-03-29 2008-02-28 Dirk Bockmuehl Composition Comprising Beta-Defensin 2
WO2011036174A1 (fr) * 2009-09-25 2011-03-31 B.R.A.I.N. Biotechnology Research And Information Network Ag Nouveau procédé de production d'un peptide antimicrobien
FR2954136A1 (fr) * 2009-12-17 2011-06-24 Oreal Composition deodorante a base de peptides antimicrobiens et procede de traitement des odeurs corporelles
WO2011132176A1 (fr) * 2010-04-23 2011-10-27 L'oreal Utilisation cosmétique d'un lysat d'espèces de bifidobacterium pour le traitement des odeurs corporelles
WO2012038929A1 (fr) * 2010-09-24 2012-03-29 L'oreal Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci
FR2980360A1 (fr) * 2011-09-27 2013-03-29 Oreal Utilisation cosmetique de l'hesperidine ou de l'un de ses derives dans la prevention et/ou le traitement des odeurs corporelles.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIEGBERT RIEG ET AL: "Generation of Multiple Stable Dermcidin-Derived Antimicrobial Peptides in Sweat of Different Body Sites", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 126, no. 2, 22 December 2005 (2005-12-22), pages 354 - 365, XP055112395, ISSN: 0022-202X, DOI: 10.1038/sj.jid.5700041 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060359A1 (fr) * 2016-12-19 2018-06-22 L'oreal Compositions cosmetiques ou dermatologiques comprenant au moins une sequence d’acide amine issue de la proteine xp32
WO2018114721A1 (fr) * 2016-12-19 2018-06-28 L'oreal Compositions cosmétiques ou dermatologiques comprenant au moins une séquence d'acides aminés provenant de la protéine xp32
CN106906180A (zh) * 2016-12-28 2017-06-30 里程 一种具有生物活化作用的复合添加剂及其制备方法和用途
WO2018120562A1 (fr) * 2016-12-28 2018-07-05 里程 Additif de composé ayant une fonction d'activation biologique, sa méthode de préparation et son utilisation
US11273114B2 (en) 2016-12-28 2022-03-15 Lei Guo Compound additive having biological activation function, preparation method therefor and use thereof
EP3360891A1 (fr) 2017-02-14 2018-08-15 Karlsruher Institut für Technologie Peptides de pénétration cellulaire d'origine humaine

Also Published As

Publication number Publication date
FR3011739A1 (fr) 2015-04-17

Similar Documents

Publication Publication Date Title
US9168215B2 (en) Cosmetic use of lacritin-type polypeptides
Presland et al. Characterization of two distinct calcium-binding sites in the amino-terminus of human profilaggrin
US20130324476A1 (en) Cosmetic use of dermicidin, and analogues or fragments thereof
WO2009001260A2 (fr) Utilisation cosmétique de protéines apolipoprotéines de type d
WO2014207181A1 (fr) Utilisation cosmétique de la dermcidine, ou d'analogues ou de fragments de celle-ci, pour prévenir et/ou traiter les odeurs corporelles et pour diagnostiquer une transpiration malodorante
JP6284897B2 (ja) アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインｉタンパク質を用いる方法
Collin et al. Protective effects of taurine on human hair follicle grown in vitro 1
Human Identification of trichohyalin-like 1, an s100 fused-type protein selectively expressed in hair follicles
Fleckman et al. Structure and function of the nail unit
EP2349319B1 (fr) Utilisation de protéines de type dj-1 pour la caractérisation d'une sécheresse cutanée
KR101231127B1 (ko) 카모듈린 유사 피부 단백질（ｃｌｓｐ）의 복합체 형태의 용도
US9926587B2 (en) Cosmetic use of chitinase-type proteins
PT1608982E (pt) Diagnóstico de autismo
US20160361384A1 (en) Cosmetic use of dermicidin, or analogues or fragments thereof, for the prevention and/or treatment and diagnosis of oily skin and aesthetic skin disorders associated therewith
US9327012B2 (en) Composition for treating, improving, or preventing pain
US10571476B2 (en) Activators of TonEBP for use for hydrating skin
FR3006890A1 (fr) Utilisation cosmetique de la dermicidine, analogues ou fragments de celle-ci pour la prevention et/ou le traitement et le diagnostic de la peau grasse et des desordres esthetiques cutanes qui y sont associes
CN101980022B (zh) 可溶性的桥粒芯糖蛋白i蛋白物质用于筛选抗衰老活性剂的用途
US20110098230A1 (en) Cosmetic use of annexin ii-type proteins for treating dryness of the skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14735526

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14735526

Country of ref document: EP

Kind code of ref document: A1